GlobeNewsWire
03 Apr 2026, 01:09 UTC · 24w ago
Verdict
Headline leans bearish. We score IMMP −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The Independent Data Monitoring Committee recommended the discontinuation of Immutep's TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer due to futility.
More negative than 99% of claims this week
Immutep's ADR price plummeted 82.6% to $0.48 following the announcement of the trial's discontinuation.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 99% of claims this week
The Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit alleging Immutep issued materially misleading business information.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company's Phase III trial was discontinued for futility, resulting in an 82.6% stock price drop and a pending class action lawsuit.
More negative than 75% of ticker scores this week
The company is the subject of a class action lawsuit filed by the Rosen Law Firm.
More negative than 75% of ticker scores this week
The company is the subject of a class action lawsuit filed by the Rosen Law Firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−27.5%
Price agrees with the score
$0.2620 vs $0.3615 close before publication (Apr 2) · not market-adjusted
IMMP chart →
